Zi Chao Zhang

Zi Chao Zhang

Auto-generated profile, based on publicly available information

Zi Chao Zhang

School of Life Science and Technology, the Key Laboratory of Developmental Genes and Human Disease, Southeast University, Nanjing, China

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2012 in Leukemia
Verified
Journal Article
Open access
JEJ Etchin
J Etchin
QSQ Sun
Q Sun
AKA Kentsis
A Kentsis
AFA Farmer
A Farmer
ZZZ C Zhang
Z C Zhang
ALA T Look
A T Look
Drugs that target the chief mediator of nuclear export, chromosome region maintenance 1 protein (CRM1) have potential as therapeutics for leukemia, but existing CRM1 inhibitors show variable potencies and a broad range of cytotoxic effects. Here, we report the structural analysis and antileukemic activity of a new generation of small-molecule inhibitors of CRM1. Designated selective inhibitors of nuclear export (SINE), these compounds were developed using molecular modeling to screen a small virtual library of compounds against the nuclear export signal (NES) groove of CRM1. The 2.2-Å crystal structure of the CRM1-Ran-RanBP1 complex bound to KPT-251, a representative molecule of this class of inhibitors, shows that the drug occupies part of the groove in CRM1 that is usually occupied by the NES, but penetrates much deeper into the groove and blocks CRM1-directed protein export. SINE inhibitors exhibit potent antileukemic activity, inducing apoptosis at nanomolar concentrations in a panel of 14 human acute myeloid leukemia (AML) cell lines representing different molecular subtypes of the disease. When administered orally to immunodeficient mice engrafted with human AML cells, KPT-251 had potent antileukemic activity with negligible toxicity to normal hematopoietic cells. Thus, KPT-SINE CRM1 antagonists represent a novel class of drugs that warrant further testing in AML patients.

15 April 2007 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
ACAhmet E Cansizoglu
Ahmet E Cansizoglu
BLBrittany J Lee
Brittany J Lee
ZZZi Chao Zhang
Zi Chao Zhang
BFBeatriz M A Fontoura
Beatriz M A Fontoura
YCYuh Min Chook
Yuh Min Chook

9 July 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
ZZZi Chao Zhang
Zi Chao Zhang
YCYuh Min Chook
Yuh Min Chook
Mutations in the proline/tyrosine–nuclear localization signal (PY-NLS) of the Fused in Sarcoma protein (FUS) cause amyotrophic lateral sclerosis (ALS). Here we report the crystal structure of the FUS PY-NLS bound to its nuclear import receptor Karyopherinβ2 (Kapβ2; also known as Transportin). The FUS PY-NLS occupies the structurally invariant C-terminal arch of Kapβ2, tracing a path similar to that of other characterized PY-NLSs. Unlike other PY-NLSs, which generally bind Kapβ2 in fully extended conformations, the FUS peptide is atypical as its central portion forms a 2.5-turn α-helix. The Kapβ2-binding epitopes of the FUS PY-NLS consist of an N-terminal PGKM hydrophobic motif, a central arginine-rich α-helix, and a C-terminal PY motif. ALS mutations are found almost exclusively within these epitopes. Each ALS mutation site makes multiple contacts with Kapβ2 and mutations of these residues decrease binding affinities for Kapβ2 ( K D for wild-type FUS PY-NLS is 9.5 nM) up to ninefold. Thermodynamic analyses of ALS mutations in the FUS PY-NLS show that the weakening of FUS-Kapβ2 binding affinity, the degree of cytoplasmic mislocalization, and ALS disease severity are correlated.

1 July 2015 in Cell
Verified
Journal Article
Closed access
JWJen-Hsuan Wei
Jen-Hsuan Wei
ZZZi Chao Zhang
Zi Chao Zhang
RWR. Max Wynn
R. Max Wynn
JSJoachim Seemann
Joachim Seemann

25 September 2013 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
YLYi Li
Yi Li
ZZZikai Zhou
Zikai Zhou
XZXinwang Zhang
Xinwang Zhang
HTHuawei Tong
Huawei Tong
PLPeipei Li
Peipei Li
JHJunhai Han
Junhai Han
Sleep is an essential and evolutionarily conserved behavior that is closely related to synaptic function. However, whether neuroligins (Nlgs), which are cell adhesion molecules involved in synapse formation and synaptic transmission, are involved in sleep is not clear. Here, we show thatDrosophilaNlg4 (DNlg4) is highly expressed in large ventral lateral clock neurons (l-LNvs) and that l-LNv-derived DNlg4 is essential for sleep regulation. GABA transmission is impaired in mutant l-LNv, and sleep defects indnlg4mutant flies can be rescued by genetic manipulation of GABA transmission. Furthermore,dnlg4mutant flies exhibit a severe reduction in GABAAreceptor RDL clustering, and DNlg4 associates with RDLs invivo. These results demonstrate that DNlg4 regulates sleep through modulating GABA transmission in l-LNvs, which provides the first known link between a synaptic adhesion molecule and sleep inDrosophila.

1 March 2007 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
FQFeng Qian
Feng Qian
YLYu-Pei Li
Yu-Pei Li
XSXia Sheng
Xia Sheng
ZZZi-Chao Zhang
Zi-Chao Zhang
RSRan Song
Ran Song
PXProfessor Qiang Xu
Professor Qiang Xu
Phosphatase of regenerating liver-3 (PRL-3) has been proposed to promote the invasion of tumor cells to metastasis sites. However, the effect of PRL-3 on spontaneous metastasis has not been clearly demonstrated, and whether PRL-3 could become a new therapeutic target in malignant tumor is still unknown. In this study, we used PRL-3 siRNA as a molecular medicine to specifically reduce the expression of PRL-3 in B16-BL6 cells, a highly metastatic melanoma cell line. In vitro, PRL-3 siRNA significantly inhibited cell adhesion and migration, but had no effect on cell proliferation. In the spontaneous metastatic tumor model in vivo, PRL-3 siRNA treatment remarkably inhibited the proliferation of primary tumor, prevented tumor cells from invading the draining lymph nodes, and prolonged the life span of mice. Therefore, our results indicate that PRL-3 plays a critical role in promoting the whole process of spontaneous metastasis and tumor growth initiation, and that inhibiting PRL-3 will improve malignant tumor therapy.